Adma Biologics reported $2.1M in Interest Expense on Debt for its fiscal quarter ending in March of 2026.





Interest Expense On Debt Change Date
Adma Biologics USD 2.1M 474K Mar/2026
Alnylam Pharmaceuticals USD 69.29M 60.05M Mar/2026
BioCryst Pharmaceuticals USD 14.14M 5.53M Dec/2025
Minerva Neurosciences USD 2.31M 60K Jun/2024
Novavax USD 5.82M 342K Dec/2025
Omeros USD 4.05M 5.16M Sep/2024
Takeda JPY 43.65B 79.98B Mar/2026